Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Takeda Pharma (TKPYY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 25,919,552
  • Shares Outstanding, K 1,562,360
  • Annual Sales, $ 15,935 M
  • Annual Income, $ 1,682 M
  • 60-Month Beta 0.42
  • Price/Sales 1.64
  • Price/Cash Flow N/A
  • Price/Book 1.36
  • Price/Earnings ttm 12.22
  • Earnings Per Share ttm 1.37
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/07/19
  • Annual Dividend & Yield 0.58 (3.48%)
  • Most Recent Dividend 0.288 on 09/27/18
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.5000 +7.03%
on 12/18/18
19.2300 -13.73%
on 11/26/18
-2.6300 (-13.68%)
since 11/21/18
3-Month
15.5000 +7.03%
on 12/18/18
21.9399 -24.38%
on 09/26/18
-4.3650 (-20.83%)
since 09/21/18
52-Week
15.5000 +7.03%
on 12/18/18
31.2900 -46.98%
on 02/01/18
-11.8100 (-41.58%)
since 12/21/17

Most Recent Stories

More News
Petra Pharma announces licensing agreement with Takeda Pharmaceutical Company

Petra Pharma Corporation ("Petra"), a leader in phosphoinositide (PI) signaling pathway inhibition, announced it has secured a global license from Takeda Pharmaceutical Company Limited ("Takeda") to develop,...

TKPYY : 16.5900 (-0.90%)
Bridge Medicines Enters Agreement with Weill Cornell Medicine to Develop a Novel Sphingosine 1-Phosphate (S1P) Receptor Modulator

Bridge Medicines announced today an agreement with Weill Cornell Medicine to develop a novel sphingosine 1-phosphate (S1P) receptor modulator. This small molecule program originated in the laboratory...

TKPYY : 16.5900 (-0.90%)
Vedolizumab (Entyvio(R)) Achieves Superior Rates of Clinical Remission vs. Adalimumab (Humira(R)) in First Ever Head-to-Head Biologic Clinical Study in Ulcerative Colitis

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced results from the Phase 3b head-to-head VARSITY study which demonstrated that the gut-selective biologic...

TKPYY : 16.5900 (-0.90%)
European Commission Approves ADCETRIS(R) (brentuximab vedotin) with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

--- Milestone Marks Fifth Approved Indication for ADCETRIS in Europe, Reinforcing Takeda's Commitment to Developing Innovative Solutions for People Living with CD30-Positive Malignancies -

TKPYY : 16.5900 (-0.90%)
Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS(R) (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the marketing...

TKPYY : 16.5900 (-0.90%)
SGEN : 72.77 (-0.12%)
Takeda to Highlight Advancements in Rare Lysosomal Storage Disorders at Global Scientific Meeting

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it will feature 12 presentations, including 11 posters and one oral presentation, at the 15th annual WORLDSymposium(TM)...

TKPYY : 16.5900 (-0.90%)
Takeda Reports Third Quarter FY2018 Results

--Reported results impacted by large one-time gains in FY2017 and Shire related costs in FY2018

TKPYY : 16.5900 (-0.90%)
TAK : 21.43 (+0.80%)
Takeda Notes Court Sanction of the Scheme of Arrangement with Respect to the Acquisition of Shire plc

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") notes Shire plc's ("Shire") announcement that the Royal Court of Jersey (the "Jersey Court") has today sanctioned the...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
Takeda Announces Multiple Cell Therapy Collaborations to Advance the Company's Novel Immuno-Oncology Portfolio

Takeda Pharmaceutical Company Limited ("Takeda") (TSE: 4502) today announced new research collaborations in immuno-oncology (I-O), an area of key strategic focus for the company. Through...

TKPYY : 16.5900 (-0.90%)
Takeda Announces Listing of American Depositary Shares on the New York Stock Exchange

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION...

BK : 51.98 (-2.15%)
TKPYY : 16.5900 (-0.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade TKPYY with:

Key Turning Points

2nd Resistance Point 17.1900
1st Resistance Point 16.8900
Last Price 16.5900
1st Support Level 16.3200
2nd Support Level 16.0500

See More

52-Week High 31.2900
Fibonacci 61.8% 25.2582
Fibonacci 50% 23.3950
Fibonacci 38.2% 21.5318
Last Price 16.5900
52-Week Low 15.5000

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar